17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications

Round 1

Reviewer 1 Report

This is a comprehensive and well written review on the importance of gain of chromosome 17q in childhood neuroblastoma. The review gives the reader an overview and detailed descriptions on why 17q gain and specifically segmental 17q gain is a genetic factor that should be further analyzed in neuroblastoma. The references used is highly relevant and extensive which gives the reader relevant information for further investigations into details.

Author Response

We would like to thank the reviewer for a generous opinion of the manuscript.

Reviewer 2 Report

The article discusses the clinical and biological significance of an increase in chromosome 17q in the development of neuroblastoma. This genetic change has been found to be an important marker of the disease and is associated with a poor prognosis. Important sites for chromosome 17q breaks are 17q12 and 17q21, where the oncogenes IGF2BP1 and NME1 are located.

While reading the article, I had some comments and recommendations:

1.      The authors divided the article into several small parts with a statement of literature data. To improve the presentation of the article, I recommend adding small conclusions to each section.

2.      It is not entirely clear why the authors did not indicate the ERBB2 gene, which is an important oncogene and which is also located on 17q. There is no information on the BRCA1 gene, which is also located on 17q.

Why did the authors focus on 17q, and not on 17p, for example, or the entire chromosome? Thus, on 17p there is the TP53 gene, which plays an important role in oncogenesis.

3.      To improve the article, it is necessary to add a critical analysis of the cited materials and focus on your concept, your vision of the problem, which prompted the authors to write a review of the data

Author Response

Please see the attachment.

Author Response File: Author Response.docx